Chemo/Immunotherapy Data Increasingly Compelling with Additional Follow-Up (BMIC-009)
Sep 25, 2017•7 min
Episode description
Dr. Jack West assesses the merits of a combination of chemotherapy with pembrolizumab (Keytruda) based on the evolving efficacy data, especially the maturing results for overall survival, with longer follow-up of the KEYNOTE-021g trial.
For the best experience, listen in Metacast app for iOS or Android
Open in Metacast